In:
PLOS ONE, Public Library of Science (PLoS), Vol. 17, No. 7 ( 2022-7-14), p. e0270590-
Kurzfassung:
Although micronutrient and antioxidant supplementation are widely used by persons with human immunodeficiency virus (HIV), a therapeutic role beyond recommended daily allowances (RDA) remains unproven. An oral high-dose micronutrient and antioxidant supplement (Treatment) was compared to an RDA supplement (Control) for time to progressive immunodeficiency or initiation of antiretroviral therapy (ART) in people living with HIV (PLWH). Methods This study was a randomized, double-blind, placebo-controlled multicenter clinical trial. PLWH were recruited from Canadian HIV Trials Network sites, and followed quarterly for two years. Eligible participants were asymptomatic, antiretroviral treatment (ART)-naïve, HIV-seropositive adults with a CD4 T lymphocyte count (CD4 count) between 375–750 cells/μL. Participants were randomly allocated 1:1 to receive Treatment or Control supplements. The primary outcome was a composite of time-to-first of confirmed CD4 count below 350 cells/μL, initiation of ART, AIDS-defining illness or death. Primary analysis was by intention-to-treat. Secondary outcomes included CD4 count trajectory from baseline to ART initiation or two years. A Data and Safety Monitoring Board reviewed the study for safety, recruitment and protocol adherence every six months. Results Of 171 enrolled participants: 66 (38.6%) experienced a primary outcome: 27 reached a CD4 count below 350 cells/μL, and 57 started ART. There was no significant difference in time-to-first outcome between groups (Hazard Ratio = 1.05; 95%CI: 0.65, 1.70), or in time to any component outcome. Using intent-to-treat censoring, mean annualized rates of CD4 count decline were -42.703 cells/μL and -79.763 cells/μL for Treatment and Control groups, with no statistical difference in the mean change between groups (-37.06 cells/μL/52 weeks, 95%CI: (-93.59, 19.47); p = 0.1993). Accrual was stopped at 171 of the 212 intended participants after an interim analysis for futility, although participant follow-up was completed. Conclusions In ART-naïve PLWH, high-dose antioxidant, micronutrient supplementation compared to RDA supplementation had no significant effect on disease progression or ART initiation. Clinical trial registration ClinicalTrials.gov Identifier : NCT00798772 .
Materialart:
Online-Ressource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0270590
DOI:
10.1371/journal.pone.0270590.g001
DOI:
10.1371/journal.pone.0270590.g002
DOI:
10.1371/journal.pone.0270590.g003
DOI:
10.1371/journal.pone.0270590.g004
DOI:
10.1371/journal.pone.0270590.t001
DOI:
10.1371/journal.pone.0270590.t002
DOI:
10.1371/journal.pone.0270590.t003
DOI:
10.1371/journal.pone.0270590.s001
DOI:
10.1371/journal.pone.0270590.s002
DOI:
10.1371/journal.pone.0270590.s003
DOI:
10.1371/journal.pone.0270590.s004
DOI:
10.1371/journal.pone.0270590.s005
DOI:
10.1371/journal.pone.0270590.s006
DOI:
10.1371/journal.pone.0270590.s007
DOI:
10.1371/journal.pone.0270590.s008
DOI:
10.1371/journal.pone.0270590.s009
DOI:
10.1371/journal.pone.0270590.s010
DOI:
10.1371/journal.pone.0270590.s011
DOI:
10.1371/journal.pone.0270590.s012
DOI:
10.1371/journal.pone.0270590.s013
DOI:
10.1371/journal.pone.0270590.s014
DOI:
10.1371/journal.pone.0270590.s015
DOI:
10.1371/journal.pone.0270590.s016
DOI:
10.1371/journal.pone.0270590.s017
DOI:
10.1371/journal.pone.0270590.s018
DOI:
10.1371/journal.pone.0270590.s019
DOI:
10.1371/journal.pone.0270590.s020
DOI:
10.1371/journal.pone.0270590.s021
DOI:
10.1371/journal.pone.0270590.s022
DOI:
10.1371/journal.pone.0270590.s023
DOI:
10.1371/journal.pone.0270590.s024
DOI:
10.1371/journal.pone.0270590.s025
DOI:
10.1371/journal.pone.0270590.s026
DOI:
10.1371/journal.pone.0270590.s027
DOI:
10.1371/journal.pone.0270590.r001
DOI:
10.1371/journal.pone.0270590.r002
DOI:
10.1371/journal.pone.0270590.r003
DOI:
10.1371/journal.pone.0270590.r004
Sprache:
Englisch
Verlag:
Public Library of Science (PLoS)
Publikationsdatum:
2022
ZDB Id:
2267670-3
Permalink